$CRBP

Moran Sean F. sold $121K of CRBP

Moran Sean F. (Chief Financial Officer) sold 12,000 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $10.08 ($0.12M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moran Sean F.
Published Aug 10, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CRBP
Neutral
high confidence
Mentioned
$CRBP
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRBPNeutralLow
01

Why it matters

The newest disclosed fact is the CFO’s open-market sale of 12,000 shares at $10.0809 on 2026-08-07, with a 10b5-1 plan noted.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide a new fundamental catalyst.

03

What to watch

The article does not state whether other insiders sold/bought around the same period, nor does it provide context on total insider holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: Filed after-hours on 2026-08-10, reflecting insider sale disclosed for 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Corbus Pharmaceuticals Holdings, Inc.

Company-level read

Ticker impact

$CRBPNeutralHigh confidence
Context

Corbus Pharmaceuticals CFO Sean Moran sold 12,000 shares in an open-market transaction at $10.0809 on 2026-08-07 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a routine Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and the article provides no new operational, financial, or regulatory catalyst.

Market effects

Minimal; single-company insider sale does not materially reset sector expectations.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not signal bearish information and could be mechanically scheduled.

Key entities

  • Corbus Pharmaceuticals Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Sean F. Moran

    Chief Financial Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRBPMed

Corbus Pharmaceuticals Holdings, Inc. (CRBP): Results of Operations and Financial Condition

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 • Concluded last

$CRBPHighAI 9/10

Corbus Pharmaceuticals Announces Updated Data From CRB-701 Study, Stock Down In Pre-Market

Corbus Pharmaceuticals (CRBP) reported updated Phase 1/2 data for CRB-701 in 2L oropharyngeal and cervical cancers, based on an April 1, 2026 cut with 317 patients. It cited ORR of 42.9% (median DOR 6.3 months, PFS 5.6) in OPSCC and 34.4% (DOR 8.0, PFS 4.3) in cervical cancer. The company plans registrational trials starting with TEMPO-1 in summer 2026; shares were down 12.79% pre-market to $9.90.